Zalicus Inc. (ZLCS) Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
5/10/2013 7:58:23 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that preclinical data highlighting its novel, oral ion channel programs for the treatment of pain including Z160, an N-type calcium channel blocker and Z944, a T-type calcium channel blocker were presented at the 32nd Annual Scientific Meeting of the American Pain Society taking place May 8-11, 2013 in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by